Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Breast 2Thoracic 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 167Neoplasm Metastasis 18Breast Neoplasms, Male 15Neoplasms 13Brain Neoplasms 11Inflammatory Breast Neoplasms 5Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Osteitis Deformans 2Lung Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Diseases 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Neoplastic Cells, Circulating 1Metastatic Breast Cancer With Intracranial Metastases 1Invasive Breast Cancer 1Insulin-Like Growth Factor I, Resistance To 1Her2 Positive Metastatic Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-Positive Early Stage Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Breast Cancer 1

Interventions

pembrolizumab 28Trastuzumab 16Paclitaxel 14Docetaxel 12Cyclophosphamide 11Capecitabine 11Nivolumab 9fludarabine 7Carboplatin 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Cisplatin 6Specimen Handling 5Leucovorin 5Irinotecan 5Injections 5Gemcitabine 5Fluorouracil 5Bevacizumab 5atezolizumab 4aldesleukin 4Taxes 4Ipilimumab 4Fluorodeoxyglucose F18 4Drug Therapy 4Cetuximab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4zanidatamab 3veliparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × Lapatinib × Breast × Clear all
NCT00313599 2014-07-02

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

University of California, San Francisco

Phase 1 Completed
28 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
60 enrolled
BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡